Rare but Treatable: The Brain Diseases Radiologists Cannot Afford to Miss

Neurogenetic diseases are individually rare, but taken together they are far from uncommon, and a growing number of them are now treatable. A comprehensive review published in Pediatric Radiology by Matthew T. Whitehead, a neuroradiologist at the Children’s Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, argues that the stakes of recognizing these disorders on brain imaging have never been higher. Advances in genetic diagnostics, the expansion of newborn screening programs, and a wave of new therapies ranging from enzyme replacement to gene therapy mean that a timely radiological suspicion can be the difference between a child who thrives and one who suffers irreversible neurodegeneration. The review, written from a neuroradiologist’s perspective, organizes the treatable inherited metabolic disorders of the brain into three broad imaging categories: white matter-dominant leukodystrophies, gray matter-dominant poliodystrophies, and conditions with distinctive magnetic resonance spectroscopy signatures.

The therapeutic landscape has changed dramatically over the past several years. Treatment options now span substrate reduction and replacement, cofactor replacement, enzyme replacement, RNA-based therapies, cell therapy, gene therapy, and gene editing. The general trend, Whitehead notes, is a movement away from ongoing metabolic replacement strategies such as dietary modification, cofactor supplementation, and enzyme replacement therapy toward single-instance genetic interventions like gene therapy and, eventually, gene editing. To keep pace with this rapidly evolving field, clinicians can consult a dynamic, continuously updated resource known as the Metabolic Treatabolome, which catalogs treatable inherited metabolic disorders. For the practicing radiologist, however, the essential message is simpler: certain reproducible patterns on MRI and MR spectroscopy should trigger immediate consideration of a treatable neurogenetic condition, because these diseases arise from selective tissue vulnerability that produces identifiable and characteristic imaging signatures.

The first challenge is knowing when to suspect a metabolic disorder at all. The imaging characteristics of neurogenetic brain diseases often overlap with far more common entities, particularly hypoxic-ischemic injury and encephalitis. Profound hypoxic-ischemic injury in neonates typically affects the posterior putamen, the posterior limb of the internal capsule, and the ventrolateral thalamus simultaneously, because these regions have high energy demands. When patterns diverge from this expectation, metabolic disease should rise on the differential. Specific red flags include deep gray nuclear lesions that spare the thalami or basal ganglia, temporally disparate lesions, brainstem-predominant abnormalities, unexplained reduction in brain volume, malformations, and chronic lesions in a newborn, none of which fit the typical timeline or distribution of oxygen deprivation or infection.

Among the white matter-dominant disorders, X-linked adrenoleukodystrophy stands out as the single most important diagnosis to know. Caused by variants in the ABCD1 gene, a peroxisomal defect, it is the most common leukodystrophy, it is treatable, and it shows a moderately specific imaging pattern: in roughly 80 percent of cases, demyelination begins in the splenium of the corpus callosum, spreads to the forceps major, descends along projection fibers, and ultimately involves auditory and visual white matter tracts. Active inflammation is marked by reduced diffusivity and contrast enhancement. Alternative phenotypes include frontal onset, deep diffuse, and projectional patterns. With the addition of ABCD1 to the recommended uniform screening panel in the United States, 47 states and the District of Columbia now perform newborn screening, and MRI surveillance identifies the fewer than half of affected boys who develop the cerebral form. Treatment, most effective early when few brain lesions exist, is allogeneic hematopoietic stem cell transplantation, with autologous gene-modified stem cell transplant as a second-line option. Patients with typical lesions and a Loes score below 10 may qualify for therapy, and post-treatment stability is defined as a Loes score below 10 or an increase of less than 6 points from baseline.

Two other leukodystrophies, Krabbe disease and metachromatic leukodystrophy, illustrate how clinical context and subtle imaging distinctions guide diagnosis. Juvenile-onset Krabbe disease can closely mimic X-linked adrenoleukodystrophy with poorly marginated splenial and forceps major abnormality, while the infantile form looks different, featuring lesions in the dentate nuclear hilus, deep cerebral hyperattenuation on CT from galactosylceramide deposition, thalamic T2 shortening, optic chiasm thickening, and enhancement of cranial nerves and the cauda equina. A striated, tigroid pattern in the corona radiata from perivascular myelin sparing is typical but not specific. Hematopoietic stem cell transplant works best before symptoms appear, ideally in the first month of life, which makes newborn screening for GALC enzyme activity, now implemented in 18 states, critically important. Metachromatic leukodystrophy shares several features with infantile Krabbe disease but usually spares the chiasm and hindbrain, may involve the genu earlier, and lacks the deep cerebral hyperattenuation. Markedly elevated myoinositol on spectroscopy and gallbladder disease, even in pre-symptomatic patients, provide additional clues. The preferred treatment is gene therapy using lentivirally modified ARSA, available for children under seven who are pre-symptomatic or only mildly symptomatic, and six states have added MLD to newborn screening panels since its endorsement.

Maple syrup urine disease demonstrates how imaging can track treatment response in real time. This aminoacidopathy typically presents at the end of the first neonatal week with encephalopathy and striking white matter edema, with symmetric, markedly reduced diffusivity and swelling in myelinating and myelinated tracts of the cerebrum, cerebellum, and brainstem. Spectroscopy reveals elevated branched-chain amino acids and ketoacids as a broad doublet near 0.9 to 1 ppm, though detecting these peaks reliably at 3 tesla requires careful echo time selection due to anomalous J-coupling. While protein restriction is necessary and leucine, isoleucine, and valine cannot be eliminated entirely from the diet, liver transplantation is considered a definitive treatment that permits a more relaxed diet. A favorable post-transplant scan shows resolution of the diffusion abnormalities and intramyelinic edema, resolution of lactate, normalization of NAA, and reduction of the branched-chain amino acid peaks, findings documented in a patient imaged seven years after curative transplantation. The mucopolysaccharidoses, a group of multi-system lysosomal storage disorders, offer another treatable example: enlarged perivascular spaces combined with skeletal changes such as a J-shaped sella, frontal bossing, and odontoid hypoplasia suggest the diagnosis, and weekly enzyme replacement therapy has been shown to resolve white matter signal abnormality and stabilize neurological symptoms in eligible patients.

Menkes disease, an X-linked copper transport disorder caused by ATP7A variants, produces one of the most visually distinctive findings in pediatric neuroradiology: diffuse marked elongation and tortuosity of the intracranial arteries, present almost always, even in neonates, because copper is essential for vessel wall integrity. Supporting findings include delayed myelination, transient tumefactive temporal lobe vasogenic edema between one and ten months of life, basal ganglia lesions with reduced diffusion, and skeletal changes such as Wormian bones and fractures. Early daily subcutaneous copper histidinate injections, which bypass the defective copper transporter, are essential for preventing severe neurodegeneration, reducing seizures, and prolonging life. On the gray matter side, Wilson disease from ATP7B variants shows basal ganglia, thalamic, midbrain, and pontine lesions with a characteristic mixed increased-and-decreased signal, where T2 signal correlates with neurological dysfunction and T1 signal with hepatic dysfunction, and the famous face of the giant panda in the midbrain may appear. Copper reduction through diet, zinc supplementation, and chelation, or curative liver transplantation, addresses the underlying metabolic derangement.

Several other gray matter disorders reward pattern recognition. Biotin-thiamine-responsive basal ganglia disease, from SLC19A3 variants, causes thalamic and cortical edema with prominent putaminal involvement, and responds, as its name promises, to lifelong biotin and thiamine supplementation. Glutaric aciduria type 1 announces itself structurally before the basal ganglia lesions appear, with underopercularization and enlarged temporopolar subarachnoid spaces, and early l-carnitine with an arginine-restricted, lysine-free diet is highly effective at preventing permanent striatal injury. Urea cycle defects produce hyperammonemic brain injury with peri-insular and deep cortical lesions that spare the thalami, a pattern unusual in hypoxic-ischemic injury, alongside elevated glutamine and glutamate with reduced myoinositol on spectroscopy; dietary management and, in neonatal-onset ornithine transcarbamylase deficiency, curative liver transplantation are the mainstays. Molybdenum cofactor deficiency type A responds to substrate replacement with cyclic pyranopterin monophosphate, and neuronal ceroid lipofuscinosis CLN2, the most common childhood neurodegenerative disease group, can be slowed by bi-weekly intraventricular cerliponase alfa, identifiable on imaging by cerebellar-predominant atrophy, thalamic T2 shortening, and subinsular signal change.

Finally, MR spectroscopy deserves special emphasis because it can be diagnostic even when the MRI appears entirely normal. Fatty acid metabolism disorders such as CPT1 deficiency produce elevated lipid peaks at 0.9 and 1.3 ppm on a normal-appearing scan, and respond to dietary modification with frequent high-carbohydrate meals and medium-chain fatty acid supplementation. Galactosemia yields a large doublet at 3.7 ppm from toxic galactitol accumulation, which inverts at intermediate echo times and normalizes with dietary change. Cerebral creatine deficiency syndromes show markedly reduced creatine peaks at 3 and 3.95 ppm, and creatine supplementation can normalize the spectrum in AGAT and GAMT deficiency. The review recommends a low threshold for adding short-echo single-voxel spectroscopy to any suspected neurometabolic case, with the voxel placed in the deep gray nuclei for poliodystrophies and parietal white matter for suspected leukodystrophies. The overarching conclusion is unambiguous: symmetric gray or white matter lesions in patterns atypical for hypoxic-ischemic injury and infection, or a characteristic spectroscopic signature, should prompt consideration of these not-to-be-missed disorders, because failure to recognize them promptly delays lifesaving and morbidity-reducing treatment.

Subject of Research: Neuroimaging patterns of treatable neurogenetic and inherited metabolic brain diseases in children

Article Title: Don’t miss this treatable neurogenetic disease!

Article References: Whitehead, M. T. (2026). Don’t miss this treatable neurogenetic disease!. Pediatric Radiology. https://doi.org/10.1007/s00247-026-06796-8

Image Credits: AI Generated

DOI: 10.1007/s00247-026-06796-8

Keywords: neurogenetic diseases, leukodystrophy, MRI, MR spectroscopy, X-linked adrenoleukodystrophy, Krabbe disease, metachromatic leukodystrophy, maple syrup urine disease, Wilson disease, newborn screening, gene therapy, pediatric neuroradiology